Lantern Pharma (LTRN) Tops Q4 EPS by 16c

Lantern Pharma (NASDAQ: LTRN) reported Q4 EPS of ($0.31), $0.16 better than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Snowflake soars 20% on earnings beat and raised guidance
• Five Below (FIVE) Tops Q2 EPS by 35c, Beats on Revenue; Offers Q3 Revenue Guidance